China API Market Size, Industry Trends, Leading Players, Share and Forecast 2019-2025

China API market is estimated to witness a growth rate of around 7.5% during the forecast period. China was the largest exporter of API globally with exporting volume of over 500 million tons in 2018. Well-developed infrastructure, large production capability, high prevalence of the chronic disease in the country such as cancer, CVD and so on are some of the factors that are responsible for the strong market growth in the country. China is the largest API supplier across the globe due to the increased focus on the pharmaceutical manufacturing sector coupled with the low production cost in the country.

Request a Free Sample of our Report on China API Market: https://www.omrglobal.com/request-sample/china-api-market

The China API market is segmented on the basis of type, type of synthesis, manufacturer type, therapeutics, and region. On the basis of type, the market is divided into a generic API and branded API. The branded API segment is estimated to be the dominant segment over the forecast period. On the basis of the type of synthesis, the market is classified into biotech API, synthetic API, and others. The synthetic API segment held the dominant position in the country's API market in 2018. Furthermore, the market is classified on the basis of therapeutics into cardiovascular drugs, oncology drugs, neurology drugs, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and others.

Some of the prominent players that contribute significantly in the China API market include Teva Pharmaceutical Industries Ltd., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Novartis International AG, Boehringer Ingelheim International GmbH, and others. These players operate in very highly competitive environment and thus adopt various strategies to stay competitive in the market. Mergers and acquisitions, new product launch, geographical expansion, manufacturing capability expansion are some of the majorly adopted strategies by these market players.

A Full Report of China API Market is Available at https://www.omrglobal.com/industry-reports/china-api-market

China API Market Segmentation

By Type
o General API
o Branded API

By Type of Synthesis
o Biotech API
o Synthetic API
o Others (High Potency API)

By Therapeutics
o Cardiovascular Drugs
o Oncology Drugs
o Neurology Drugs
o Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
o Others (Orthopedic Drugs)

Company Profiles
o AbbVie Inc.
o Aesica Pharmaceuticals, Ltd.
o Almac group PLC
o AstraZeneca PLC
o Aurobindo Pharma Ltd.
o Boehringer Ingelheim International GmbH
o Cambrex Corp.
o Cipla Ltd.
o CordenPharma GmbH
o EsteveQuímica, S.A.
o Fareva SA
o Pfizer, Inc.
o Novartis International AG
o Sanofi SA
o Bristol-Myers Squibb Co.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-api-market

For More Information, Visit https://www.omrglobal.com/

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.